IBCSG 15-95

  • High dose EC x 3 supported by PBSC vs. EC/AC x 4 followed by CMF as adjuvant treatment for high risk operable stage II and stage III breast cancer in premenopausal and young postmenopausal (less than 65 years) patients

  • Study Chairs
    Dr. Russel Basser - Melbourne, Australia
    Prof. Monica Castiglione - Bern, Switzerland

    Statistician
    Dr. Zhouxin Sun

    Director of the Data Management Center
    Holly Shaw

    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    Date of Activation
    July 1995

    Date of Closure
    March 15, 2000

    Targeted Accrual
    300 patients

    Final Accrual
    344 patients

    Date of Discontinued Follow-up
    December 31, 2011

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org

Member Login